PCSA PROCESSA PHARMACEUTICALS INC revenue, earnings and financials
For the quarter ended June 30, 2026, PROCESSA PHARMACEUTICALS INC reported revenue of n/a, net income of −$3.27M and diluted EPS of −$1.19; for the fiscal year ended December 2025 revenue was n/a.
PCSA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$14.0M, net income −$13.6M (margin n/a), EPS −$10.36
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$12.1M, net income −$11.9M (margin n/a), EPS −$96.78
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$11.5M, net income −$11.1M (margin n/a), EPS −$8.48
- Fiscal year ended Dec 2022: revenue $0, gross profit n/a, operating income −$27.5M, net income −$27.4M (margin n/a), EPS −$34.05
- Fiscal year ended Dec 2021: revenue $0, gross profit n/a, operating income −$12.1M, net income −$11.4M (margin n/a), EPS −$0.75
PCSA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$3.27M, EPS −$1.19
- Quarter ended Mar 31, 2026: revenue n/a, net income −$3.38M, EPS −$1.29
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$3.36M, EPS $3.55
- Quarter ended Sep 30, 2025: revenue n/a, net income −$3.44M, EPS −$0.07
- Quarter ended Jun 30, 2025: revenue n/a, net income −$3.93M, EPS −$6.26
- Quarter ended Mar 31, 2025: revenue n/a, net income −$2.83M, EPS −$7.58
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$2.73M, EPS −$93.63
- Quarter ended Sep 30, 2024: revenue n/a, net income −$3.38M, EPS −$1.03
- Quarter ended Jun 30, 2024: revenue n/a, net income −$3.01M, EPS −$1.01
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.73M, EPS −$1.11
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$2.41M, EPS −$1.47
- Quarter ended Sep 30, 2023: revenue n/a, net income −$2.08M, EPS −$1.54
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.61M, EPS −$1.94
- Quarter ended Mar 31, 2023: revenue $0, net income −$4.02M, EPS −$3.53
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$13.0M, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income −$6.02M, EPS −$0.37
- Quarter ended Jun 30, 2022: revenue n/a, net income −$5.16M, EPS −$0.32
- Quarter ended Mar 31, 2022: revenue $0, net income −$3.23M, EPS n/a
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$3.18M, EPS −$0.22
- Quarter ended Sep 30, 2021: revenue n/a, net income −$2.99M, EPS −$0.19
PCSA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$11.4M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$11.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$8.06M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$9.61M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$8.72M, share buybacks n/a
PCSA balance sheet
- Jun 30, 2026: cash $196K, total assets $2.07M, total liabilities $2.39M, shareholders' equity −$317K
- Mar 31, 2026: cash $1.69M, total assets $4.52M, total liabilities $1.98M, shareholders' equity $2.54M
- Dec 31, 2025: cash $5.54M, total assets $7.81M, total liabilities $2.24M, shareholders' equity $5.58M
- Sep 30, 2025: cash $6.31M, total assets $7.58M, total liabilities $1.75M, shareholders' equity $5.83M
- Jun 30, 2025: cash $6.94M, total assets $8.18M, total liabilities $2.07M, shareholders' equity $6.11M
- Mar 31, 2025: cash $2.90M, total assets $4.81M, total liabilities $1.28M, shareholders' equity $3.53M
- Dec 31, 2024: cash $1.19M, total assets $3.23M, total liabilities $1.53M, shareholders' equity $1.70M
- Sep 30, 2024: cash $2.89M, total assets $4.94M, total liabilities $1.22M, shareholders' equity $3.72M
Is PCSA profitable?
No. PROCESSA PHARMACEUTICALS INC lost $13.4M over the last four quarters.
What is PCSA's EPS?
Diluted earnings per share over the last four quarters were $1.00; −$1.19 in the latest quarter.